Xbrane Biopharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-73.91	-	-	-322.03	-172.51	-188.38
Depreciation & Amortization	-	21.14	35.95	-	-	-
Other Adjustments	29.64	-147.99	-110.13	34.51	9.33	7.18
Change in Receivables	34.55	70.03	-4.56	-85.13	1.7	-61.09
Changes in Inventories	32.45	48.98	-166	-56.6	-50.26	-
Changes in Accounts Payable	-150.59	-368.78	212.82	22.57	17.83	22.67
Changes in Income Taxes Payable	-2.32	-2.23	-11.59	-	-	-
Changes in Other Operating Activities	-	-0.51	-0.44	-0.65	-9.88	-10.4
Operating Cash Flow	-130.31	-250.69	-133.73	-406.68	-193.92	-219.61
Capital Expenditures	-0.11	-	-0.5	-6.79	-11.62	-27.68
Purchases of Intangible Assets	-90.07	-139.64	-51.75	-9.98	-48.51	-49.67
Other Investing Activities	5	102.5	-	-	-	-
Investing Cash Flow	-85.17	-37.14	-52.25	-16.77	-60.13	-77.35
Long-Term Debt Issued	57.6	77.6	70	225	-	-
Long-Term Debt Repaid	-20	-43.5	-112.5	-20.83	-	-
Net Long-Term Debt Issued (Repaid)	37.6	34.1	-42.5	204.17	-	-
Issuance of Common Stock	240	240	337.24	120.02	170.55	380.87
Net Common Stock Issued (Repurchased)	240	240	337.24	120.02	170.55	380.87
Other Financing Activities	-14.41	-18.5	-51.12	-25.49	-21.69	-32.03
Financing Cash Flow	263.19	255.61	243.62	298.7	148.86	349.37
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-9.44	-6.05	0.84	-4.49	4.05	1.39
Net Cash Flow	47.7	-32.23	57.65	-124.75	-105.18	52.41
Free Cash Flow	-130.42	-250.69	-134.23	-413.47	-205.53	-247.29
FCF Margin	-156.58%	-164.55%	-90.64%	-173.20%	-356.72%	-2309.16%
Free Cash Flow Per Share	-0.17	-15.25	-8.17	-87.29	-1004.76	-1310.16
Levered Free Cash Flow	-157.97	-140.05	-238.47	-225.47	-226.44	-203.78
Unlevered Free Cash Flow	-184.42	-331.08	-35.66	-338.18	-206.58	-191.87